Skip to main content
SpringerLink
Log in

Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights

  • Heart Failure Prevention (W Tang, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245. doi:10.1161/CIR.0b013e31828124ad.

    Article  PubMed  Google Scholar 

  2. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.

    Article  CAS  PubMed  Google Scholar 

  3. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296(18):2209–16. doi:10.1001/jama.296.18.2209.

    Article  CAS  PubMed  Google Scholar 

  4. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.02.092.

    Google Scholar 

  5. Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.

    Article  PubMed  Google Scholar 

  6. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.

    Article  PubMed  Google Scholar 

  7. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett Jr JC, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306(8):856–63. doi:10.1001/jama.2011.1201.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014;63(5):407–16. doi:10.1016/j.jacc.2013.10.063.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart. 2006;92(9):1259–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102(15):1788–94.

    Article  CAS  PubMed  Google Scholar 

  11. Sutherland GR, Di Salvo G, Claus P, D’Hooge J, Bijnens B. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr. 2004;17(7):788–802. doi:10.1016/j.echo.2004.03.027.

    Article  PubMed  Google Scholar 

  12. Caudron J, Fares J, Bauer F, Dacher JN. Evaluation of left ventricular diastolic function with cardiac MR imaging. Radiographics. 2011;31(1):239–59. doi:10.1148/rg.311105049.

    Article  PubMed  Google Scholar 

  13. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107–33. doi:10.1016/j.echo.2008.11.023.

    Article  PubMed  Google Scholar 

  14. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol. 1997;30(1):8–18.

    Article  CAS  PubMed  Google Scholar 

  15. Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y, et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res. 2000;86(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  16. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–94.

    Article  CAS  PubMed  Google Scholar 

  17. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res. 2004;94(12):1533–42.

    Article  CAS  PubMed  Google Scholar 

  18. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22(7):1186–90.

    Article  CAS  PubMed  Google Scholar 

  19. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121(4):519–28. doi:10.1161/CIRCULATIONAHA.109.883777.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113(16):1966–73. doi:10.1161/CIRCULATIONAHA.105.587519.

    Article  PubMed  Google Scholar 

  21. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein C: its role in physiology and disease. Circ Res. 2004;94(10):1279–89. doi:10.1161/01.RES.0000127175.21818.C2.

    Article  CAS  PubMed  Google Scholar 

  22. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670–9. doi:10.1093/eurheartj/ehq426.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res. 2013;97(3):464–71. doi:10.1093/cvr/cvs353.

    Article  CAS  PubMed  Google Scholar 

  24. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15. doi:10.1038/nrcardio.2014.83.

    Article  CAS  PubMed  Google Scholar 

  25. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4(1):23–36. doi:10.1016/j.hfc.2007.10.001.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107(5):714–20.

    Article  PubMed  Google Scholar 

  27. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011;124(1):24–30. doi:10.1161/CIRCULATIONAHA.110.979203.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012;14(7):718–29. doi:10.1093/eurjhf/hfs052.

    Article  PubMed  Google Scholar 

  29. Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail. 2012;5(2):144–51. doi:10.1161/CIRCHEARTFAILURE.110.959668.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Ren X, Ristow B, Na B, Ali S, Schiller NB, Whooley MA. Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol. 2007;99(12):1643–7.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart. 2010;96(7):528–32. doi:10.1136/hrt.2009.177980.

    Article  PubMed Central  PubMed  Google Scholar 

  32. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010;55(4):300–5.

    Article  PubMed  Google Scholar 

  33. McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011;58(20):2095–103. doi:10.1016/j.jacc.2011.07.042.

    Article  CAS  PubMed  Google Scholar 

  34. Zouein FA, de Castro Bras LE, da Costa DV, Lindsey ML, Kurdi M, Booz GW. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol. 2013;62(1):13–21. doi:10.1097/FJC.0b013e31829a4e61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110(6):841–50. doi:10.1161/CIRCRESAHA.111.258251.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008;117(20):2626–36. doi:10.1161/CIRCULATIONAHA.107.737031.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293(5):H2860–9. doi:10.1152/ajpheart.01167.2006.

    Article  CAS  PubMed  Google Scholar 

  38. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E, et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology. 2010;117(3):234–42. doi:10.1159/000322905.

    Article  CAS  PubMed  Google Scholar 

  39. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92. doi:10.1056/NEJMoa1313731.

    Article  CAS  PubMed  Google Scholar 

  40. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781–91. doi:10.1001/jama.2013.905.

    Article  CAS  PubMed  Google Scholar 

  41. Clarkson PB, Wheeldon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation. 1996;93(11):2037–42.

    Article  CAS  PubMed  Google Scholar 

  42. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97(8):4239–44. doi:10.1073/pnas.070371497.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett Jr JC. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012;60(22):2305–12. doi:10.1016/j.jacc.2012.07.056.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077.

    Article  PubMed  Google Scholar 

  45. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61227-6.

    Google Scholar 

  46. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104(11):1248–54.

    Article  CAS  PubMed  Google Scholar 

  47. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573–80. doi:10.1136/hrt.2007.117978.

    Article  CAS  PubMed  Google Scholar 

  48. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004;6(4):453–61. doi:10.1016/j.ejheart.2004.02.003.

    Article  CAS  PubMed  Google Scholar 

  49. Westermann D, Becher PM, Lindner D, Savvatis K, Xia Y, Frohlich M, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107(6):308. doi:10.1007/s00395-012-0308-y.

    Article  PubMed  Google Scholar 

  50. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013:1–10. doi:10.1001/jama.2013.2024

  51. Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66–74. doi:10.1001/jama.2013.7588.

    Article  CAS  PubMed  Google Scholar 

  52. Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (HOPE) study. Circulation. 2003;107(9):1284–90.

    Article  CAS  PubMed  Google Scholar 

  53. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113(18):2201–10. doi:10.1161/CIRCULATIONAHA.105.544031.

    Article  CAS  PubMed  Google Scholar 

  54. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75(14):894–903.

  55. Zhang X, Chen C. A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine. 2012;41(3):398–409. doi:10.1007/s12020-012-9623-1.

    Article  CAS  PubMed  Google Scholar 

  56. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond). 2004;107(6):539–57. doi:10.1042/CS20040057.

    Article  CAS  Google Scholar 

  57. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8(3):136–41.

    Article  PubMed  Google Scholar 

  58. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70(4):479–87.

    Article  CAS  PubMed  Google Scholar 

  59. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84. doi:10.1001/jama.2012.120.

    Article  CAS  PubMed  Google Scholar 

  60. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223–5.

    Article  PubMed  Google Scholar 

  61. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1225–7. doi:10.1016/j.jacc.2006.07.015.

    Article  CAS  PubMed  Google Scholar 

  62. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48. doi:10.1056/NEJMoa0908355.

    Article  CAS  PubMed  Google Scholar 

  63. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13. doi:10.1056/NEJMoa020245.

    Article  PubMed  Google Scholar 

  64. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165(1):55–61. doi:10.1001/archinte.165.1.55.

    Article  PubMed  Google Scholar 

  65. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999;99(9):1173–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Chen received Research Grants from the National Institutes of Health PO1 HL 76611, R01 HL-84155, and Scios, Inc.; Mayo Clinic has filed patents for chimeric natriuretic peptides; Mayo Clinic has licensed patents to Capricor Therapeutics and Anexon with other patents pending at the US patent office; Dr. Chen received royalties from Capricor Therapeutics, Anexon, Inc., and UpToDate and is the cofounder of Zumbro Discovery, Inc.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Siu-Hin Wan has no relevant conflicts. Horng Chen has grants from the National Institutes of Health, non-financial support from Mayo Clinic, others from Zumbro Discovery, and grants from Scios, Inc., outside the submitted work. In addition, Dr. Chen has a patent Capricor Therapeutics, Anexon, Inc., and UpToDate with royalties paid.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA

    Siu-Hin Wan & Horng H. Chen

  2. Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, 55905, USA

    Siu-Hin Wan & Horng H. Chen

Authors
  1. Siu-Hin Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Horng H. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Horng H. Chen.

Additional information

This article is part of the Topical Collection on Heart Failure Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wan, SH., Chen, H.H. Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights. Curr Cardiovasc Risk Rep 9, 40 (2015). https://doi.org/10.1007/s12170-015-0466-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-015-0466-1

Keywords

Search

Navigation